Sirona Biochem Announces Proposed Strategic Equity Investment
Momentum Public Relations
Press Release: July 9, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona“) is pleased to announce it has arranged a non-brokered private placement for gross proceeds of $1,000,000. The private placement consists of 2,500,000 units, (the “Units”) at a price of $0.40 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.60 per share subject to an acceleration clause.
The Company is proposing to pay a finder’s fee to an agent or agents that assist in procuring the proceeds of the offering. Such Fee shall consist of a cash fee equal to no more than 8% of the total proceeds of the Private Placement placed by such finder and warrants up to 8% of the number of Units the finder sells in the Private Placement (the “Finder’s Warrants“). The Finder’s Warrants will be exercisable into one additional Share of the Company at a price of CAD$0.60 per Share for a period of 3 years from the closing date of the Private Placement.
Sirona Biochem is offering the strategic financing to diversify its shareholder base to include Asia-based investors who wish to establish an initial equity position in the company. The funds from this financing, in addition to general working capital, will be used to establish Asian-based manufacturing for TFC-1067.In addition, proceeds from the private placement will also be allocated to accelerate Sirona’s anti-ageing and anti-wrinkle projects.
“We are excited about this financing, principally because it positions strategic investors that will strengthen ties to our expanding presence in Asia“, reports Dr. Howard Verrico, CEO of Sirona Biochem. “Sirona now has a healthy balance sheet that will allow us to focus on continued growth of the company.”
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2019/09/c1040.html
Contact:
Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com
- Published in News Home, Sirona Biochem, Uncategorized
Grown Rogue International Inc. (CNSX: GRIN) Enjoying Robust Growth After Six-Fold Revenue Increase
Improved operational efficiency is one of the factors behind Grown Rogue International Inc. (CNSX: GRIN) stellar performance in the second quarter. A six-fold increase in revenues sets the stage for what could turn out to be a record-breaking year for the licensed cannabis operator.
Grown Rogue Q2 Financial Results
The company’s stock has gained approximately 20% since announcing it’s Q2 financial results which could well be attributed to growing investors’ confidence about the company’s growth metrics and long term prospects.
After making a name for itself in Oregon and California cannabis marketplace, Grown Rogue is once again expanding its footprint into Michigan in pursuit of opportunities for growth. With the expansion drive, the company is planning to accelerate sales growth after reporting $1.9 million in sales in Q2, representing a 548% year over year increase.
Sales growth in Q2 was mostly driven by internal sales force as well as third-party distribution and strengthening of the company’s brand. Gross margins ballooned to $0.4 million from 0.04% million a year, accounting for 20% of revenues. Improvement in gross margin was mostly as a result of refined cultivation process that led to lower costs of sales.
General and administrative expenses more than doubled in the quarter to $1.3 million attributed to an expanded scope of operations associated with sales, general and administrative support. Grown Rogue ended the quarter with an adjusted EBITDA loss of $1 million compared to a net loss of $0.6 million reported a year earlier. Management attributes the wider than expected loss to increased infrastructure investments that continue to support growth plans.
According to the Chief Executive Officer, Obie Strickler, second quarter revenue results underscore brand strength and distribution reach in the Oregon area. The company is planning to replicate the same performance in California and Michigan, other cannabis markets that represent significant opportunities for growth.
“The proposed acquisition of Decibel Farms announced in April is expected to increase our manufacturing capacity in Oregon, where we continue to enjoy record demand for our products. Our California distribution license went into effect during the second quarter with revenues expected to commence this month,” explained Mr. Strickler.
The company’s production capacity is poised to more than double to 5,400 kgs with the acquisition of Decibel Farms. Grown Rogue is also in the process of integrating a 40,000 square feet greenhouse as it continues to ramp up its production capacity.
Grown Growth Expansion Drive
Some of the key highlights in the second quarter included cannabis cultivation in Oregon expected to increase the overall yield by 50%. California expansion is already gaining traction thanks to the integration of a 16,000 sq. ft. facility. Grown Rogue has since strengthened its retail, processing, distribution operations as it seeks to ramp up sales effort in the state.
In Michigan, the company has signed a letter of intent as it seeks to acquire Inferno Gardens that will provide it with a head start in the market. With the acquisition, the company will gain access to a retail dispensary as well as an indoor cultivation and processing facility. The manufacturing facility is still under construction and expected to be operational before the end of the year.
Michigan being host to the second largest medical cannabis population presents a unique opportunity for the company given the size of the target audience. The market is thus expected to provide unique sales opportunities expected to strengthen Grown Rogue revenue base.
“Our facility in Muskegon will have the capacity to produce approximately 4,000 lbs. (~1814 kg) yearly of premium cannabis. This translates to $13-14 million in yearly revenue using today’s average market prices in Michigan,” stated Jacques Habra, Chief Strategy Officer of Grown Rogue.
The investments made have helped strengthen Grown Rogue’s core business as well as revenue base thus affirming growth metrics. The future can only be bright as the company moves to capture a wider target audience as it also continues to ramp up its cannabis production capacity.
https://ca.finance.yahoo.com/news/grown-rogue-second-quarter-revenue-123800178.html
https://ca.finance.yahoo.com/news/grown-rogue-reaches-binding-agreement-125300305.html
- Published in Uncategorized
Gold Explodes To Six-Year Highs What Next?
Gold prices are flirting with six-year highs after surging by more than 10% from this year lows. As the price continues to test resistance levels last registered in 2013, daily momentum appears to be deep in overbought territories. A pullback could thus be in the offing pending further upside action. A spike in gold prices has once again triggered renewed investor interest on gold stocks with the likes of Vanstar Mining Resources Inc. (CVE: VSR) and Crystal Lake Mining Corp (CVE: CLM) seeing increased market activity.
Gold Price Analysis
After a long period of consolidation, Gold did take out the $1350 resistance level on its way to the $1400 level. A spike to the $1437 level appears to have elicited some selling pressure as the yellow metal has since pulled lower. The $1400 level has since emerged as the immediate support level supporting further upside action in continuation of the bullish momentum.
A spike to six years high was not expected this fast. This explains the recent pullback. However, Gold remains bullish, given the underlying developments that continue to support price action.
Gold Price Catalyst
In recent months, Gold has assumed its haven status amidst growing concerns about the health of the global economy compounded by trade tensions between economic powerhouses. Geopolitical tension pitying the U.S and Iran has also forced many investors to shift their investments into safe-haven assets such as Gold as the threat of a full-blown war becomes real by the day.
The Federal Open Market Committee retaining interest rates but leaning more dovish has also triggered weakness in the U.S dollar consequently fuelling a spike in the precious metal price. The committee warned that it would cut interest rates should the U.S economy begin to show signs of a slowdown has also worked in favour of gold prices given the weakness it has triggered on the U.S dollar.
Dovish monetary statements by the U.S central bank as well as the European Central bank raises serious concerns about the health of the global economy. Gold tends to outperform the overall market in times of uncertainties, given its haven status.
Gold safe-haven demand should continue to rise should the U.S and Iran fail to reach an agreement that would bring to end tension in the gulf. Should the U.S unleash military power against Tehran following the shooting of its military surveillance drone, then it is likely that Gold will spike even higher as investors rush towards safe havens.
Gold Stocks Performance
Higher gold prices work in favour of companies engaged in the exploration and mining of the precious metal given the higher returns expected as prices surge. Vanstar mining resources is one such company that has started seeing renewed investor interest if recent market activity is anything to go by. In partnership with IAMGOLD, the company is currently working on the development of Nelligan Project believed to play host to huge gold prospects.
Crystal Lake Mining is another company engaged in the exploration of metal resources in Canada. The company is currently exploring for Gold, nickel, cobalt, and copper at its flagship properties in Emo Ontario. The company has also expanded the size of its Newmont Lake Project, thereby becoming the largest landholder in broader Eskay camp.
The fact that Gold remains bullish given the uncertainties on global economic growth, as well as geopolitical tensions, should continue to support a spike in gold-focused stocks with solid fundamentals. Above the $1400 level, gold prices should continue to rise. A breach of the support level could result in Gold dropping back to the $1361 support level.
- Published in Uncategorized
Crystal Lake Mining Continues to Make Progress in Canada’s Challenging Mining Sector
Crystal Lake Mining (CLM.V), announced it has managed to identify a new large target area – the so-called Chachi Corridor – with the high-grade gold potential on the eastern side of its Newmont Lake Project (Northwest B.C.’s Eskay Camp). Accordingly, the area is considered to be “notably underexplored”, and will act as one of the focus areas this upcoming summer.
“The newly exposed prospective ground makes the entire Chachi Corridor a high priority target”, the company said in a statement.
The Lake Country-based firm, which is engaged in the identification, acquisition and exploration of prospective mineral properties in Canada, continues to make steady progress in identifying and creating new mineral discoveries in Canada.
This news comes only a few weeks after the company announced it has successfully raised nearly $4.6 million from a private placement financing. In March, the company was forced to increase its private placement due to strong investor demand.
The majority of the raised funds, at least $3 million, will be used to complete the first phase of Crystal Lake’s 2019 drilling and exploration program at the Newmont Lake Project, while the rest is expected to be used mainly for general working capital purposes. As of today, Crystal Lake Mining has a market share of $33.3 million, which signifies a 38% increase compared to $24 million in February this year.
In order to acquire a 100% interest in the Newmont Lake Project, the firm must spend at least $8 million on exploration over the next three years; CLM pays Romios Gold Resources $2 million in installments and issue 12 million Crystal Lake shares to Romios over a three-year period.
Although the recently published “Risks and opportunities for mining – Outlook 2019” report published by KPMG still sees Canada as one of the major global hubs in the mining industry, its companies face great challenges in the context of regulation and scrutiny in order to get their key mining projects going. The Mining Association of Canada (MAC) has also warned that its companies are falling behind in the new global mining order.
“The value of total projects planned and under construction from 2018 to 2028 has been reduced by 55% since 2014, from $160 billion to $72 billion”, it is stated in the “Facts and Figures” annual report released by MAC.
For this exact reason, the new Chachi Corridor project is seen as a boost, not just for Crystal Lake Mining and its ambition to take a big step towards a more notable role in Canada’s crowded mining sector, but also for Canada’s entire mining industry.
Overall, Crystal Lake Mining is well-positioned to gain larger market share, particularly given the overall potential of the Newmont Lake Project, in addition to the expected higher demand for minerals given the global trend of a mass electrification.
- Published in Uncategorized
Element 79 name change to Mondias Natural, rollback
Momentum Public Relations
Press Release: November 26, 2018
Also New Listing (C-NHP) Mondias Natural Products Inc
Pursuant to a special resolution passed by shareholders on Dec. 20, 2017, the company has consolidated its capital on a one-new-for-1.5-old basis. The name of the company has also been changed from Element 79 Capital Inc. to Mondias Natural Products Inc.
Effective at the opening of business on Wednesday, Nov. 28, 2018, the common shares of Mondias Natural Products will commence trading on the TSX Venture Exchange, and the common shares of Element 79 Capital will be delisted.
Postconsolidation and posttransactional capitalization: unlimited number of common shares with no par value, of which 63,135,805 common shares will be issued and outstanding
Escrow: 36,333,334 common shares, of which 3,633,333 common shares are released at the date of this bulletin
Transfer agent: Computershare Investor Services Inc., Montreal and Toronto
Trading symbol: NHP (new)
Cusip No.: 60922M100 (new)
- Published in Business, Life Sciences, Mondias Natural, News Home, Uncategorized
Diagnos Five Years Ahead of Google in Diabtetic Retinopathy Screening Says Harvard Professor
Diabetic Retinopathy Market Predicted to Hit US$10.11 Billion by 2022
Diagnos Launches Hypertension Screening Application
AI Healthcare Applications Expected to Grow at 52% CAGR Between 2017-2022, Hitting US$7.98 Billion
Momentum Public Relations
Blog: September 24, 2018
On September 14th, 2018 Diagnos (TSXV: ADK) held an investor presentation at a downtown Montreal bistro for retail and institutional investors. Diagnos’ flagship product is CARA, computer aided retinal analysis, a cost efficient diabetic retinopathy screening application running on the company’s artificial intelligence platform Flaire. The company has been going from triumph to triumph this year. One indication of that was the presence of Chinese investment fund representatives.
During the presentation, recently appointed Diagnos Board member Dr. Reed Maclellan described the company’s technology as being “light years ahead of the competition. I was at a recent conference and nobody, not even Google can do what Cara can. Cara can detect macular degeneration. This is the only technology in the world that can do it. Diagnos is five years ahead of Google.”
Maclellan is an adjunct professor at both Harvard and the Boston Children’s Hospital where he teaches surgery. A microcirculation specialist, Dr. Maclellan also lectures internationally and frequently speaks at conferences of the American College of Surgeons, the Plastic Surgeons Research Council and the International Society of Vascular Anomalies.
Diagnos develops screening tools that help health care providers cut costs and make early diagnoses. Cara is designed to detect diabetic retinopathy and has the potential to prevent 85-90% of diabetes induced vision loss through early detection. At last count Cara has screened 222,034 patients, in 16 countries, using 131 screening sites. If untreated diabetic retinopathy leads to blindness.
The company is currently conducting its first Canadian pilot project in Montreal at CHUM, the Centre hospitalier de l’Universite de Montreal. If the pilot project is a success, Larente expects to be setting up Cara screening centres in hospitals and clinics across Quebec. CHUM has 35,000 diabetics, 80% of whom have never had a retina screening. Once you are a diabetic you face a 50% chance of going blind.
“Our job,” Larente, Diagnos’ president said in an earlier interview, “is to screen those 35,000 diabetics and send the ones that are critical right to the ophthalmology department and mange the other ones. Manage means you come every year and you get your test done.”
Once the pilot project is completed Larente expects to see Cara screening facilities in Quebec hospitals and just as a successful pilot project in Mexico led to a government contract, he expects the CHUM pilot project to result in a contract with the Quebec Ministry of Health.
“This will actually reduce the cost to the government because now you are going to manage the diabetic population. When you start to have retinopathy you can treat the patient. There is diet, there are vitamins. There are small inexpensive treatments to make sure it doesn’t go to the critical stage. There is a very effective laser treatment for bleeding.”
The diabetic retinopathy market is growing at 6.8% CAGR and according to a news release issued by Million Insights will grow from US$5.9 billion in 2014, to US$10.11 billion in 2022.
During the presentation, Diagnos president Andre Larente, announced that while the company intended to keep on marketing to government health agencies it also intended to beef up its approach to targets like hospitals and health care providers.
Drawing on his own experience, Maclellan described why AI powered medical devices had an initial slow adoption rates. “People were afraid it would take their jobs.” That has now changed. “Once one hospital starts using it, Cara adoption will snowball.”
To show just how much AI driven platforms are gaining traction in medicine at the beginning of 2018 Research House Frost & Sullivan predicted that by 2025, 85% of surgical procedures are likely to be done by robots.
According to Market and Markets, the market for artificial intelligence applications in healthcare will grow from US$667.1 million in 2016 to US$ 7.98 billion in 2022, growing at a CAGR of 52.68% during the forecast period.
Diagnos’ product line is expanding. In July the company launched the first application in its Cardio product line, Cara HTA. The application uses the same fundus camera used for diabetic retinopathy to screen for hypertensive retinopathy. Cara HTA also monitors the efficacy of blood pressure treatments which will allow doctors to monitor and adjust treatment as necessary.
From a revenue standpoint, Cara HTA offers the same form of recurring revenues that screening for diabetic retinopathy does. Once the screening has been initially performed patients will require additional screenings on an annual or as needed basis.
The hypertension market is huge. Almost one in two adult Americans, for example, suffer from high blood pressure, a precursor to strokes and heart attacks.
Diagnos also has a third product in development, Cara Cardio which will screen for cardiovascular disease and debut during 2019. In September Diagnos signed two agreements. The first was with another Montreal-based company Optina Diagnostics, to provide a telemedicine platform based on Cara for a period of three years. Optina will use Diagnos Cloud Services to upload images generated by Optina’s hyperspectral camera for the early detection of Alzheimer’s.
The company believes that the agreement will attract other biotech companies that need a telemedicine platform. Cara includes a telemedicine platform that allows all the medical professionals involved to see the same picture. Additionally the company has already successfully incorporated blockchain technology to maintain patient confidentiality.
In September the company also signed a three year agreement with American company 20/20NOW to provide diabetic retinopathy screening services. 20/20NOW is a pioneer in ocular telehealth.
September has been a good month for Diagnos, the future should be even better.
- Published in Blog, Diagnos, Life Sciences, News Home, Technology, Uncategorized
Crop Completes Purchase of Nye County Farm
Momentum Public Relations
Press Release: September 7, 2018
CROP Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (“CROP“ or the “Company“) announced today that it has completed the member interest purchase agreement with Elite Ventures LLC, of Nevada, to acquire a 49% member interest in the Nye County agricultural property. The company has agreed to pay $1,350,000 USD in cash and has currently loaned $1,697,148 USD for the property and equipment expenses, with no more than $200,000 in additional expenses expected for this first harvest.
The Nye County agricultural property is in central Nevada and was selected for its temperate climate which is ideal for greenhouse and outdoor growing. The property totals over 315 acres and includes 300 acres of private water rights, with 240 acres under automatic irrigation pivots that also have automatic fertilizer injection systems installed.
The previously announced 240 acres of CBD Hemp has been planted and is currently 2.5-3 feet tall and growing under pivot with the resulting harvest expected within 45 days. A recent plant count suggests 3,000 healthy plants per acre or 720,000 plants under pivot. All harvesting equipment has been secured for the resulting hemp biomass. The cost of production was not expected to exceed $700,000, with $350,000 incurred to date, and no more then $200,000 in additional costs expected to prepare our tenant for this harvest.
CROP Infrastructure Director and CEO, Michael Yorke, stated: “We are pleased to have completed this acquisition and see our operations coming in under budget for this first harvest. This further demonstrates that our tenant and brand licensee was the correct choice for our Nevada farm. The next phase of development will be a state-of-the-art extraction facility to make high-value CBD isolate.”
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California and Washington State, Nevada, Italy, Jamaica and a joint venture on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of 16 Cannabis brands and has US and Italian distribution rights to a line of over 55 cannabis topical products from The Yield Growth Corp.
- Published in Business, CROP Infrastructure, Medical Marijuana, News Home, Uncategorized
Total Canadian Marijuana Sales to Hit $7.17 Billion in 2019
Deloitte: Total Canadian Marijuana Sales to Hit $7.17 Billion in 2019
Legal Use Expected to Rise by 35%
When Investing Remember, There’s More Than One Way to Skin a Cat
The marijuana market and industry have grown so far and so fast in the last year that it is sometimes difficult to get a handle on it but one thing is clear. It is going to be a huge market.
A report on the emerging marijuana market by Deloitte puts legal, illegal and medical marijuana sales in Canada at $7.17 billion for 2019. According to a May 9, 2018 CBC story The Canadian Imperial Bank of Commerce pegs Canadian marijuana consumption over the next two years at 800,000 kilograms and that by 2020, the recreational market will approach $6.5 billion. To put that sum into perspective $6.5 billion is more than Canadians spend on liquor.
As of August 29, 2018, according to Bloomberg, the biggest Canadian marijuana producer, Canopy Growth, TSX: Weed, was trading at $58.39 a share and had a market cap of $12.569 billion.
The soaring prices of licensed producers may make many decide that investing in marijuana is just too expensive, however, there is more than one way to skin a cat.
There are a number of ways to invest in the marijuana gold rush that don’t involve spending the mortgage money. It isn’t just the licensed growers that are growing in value. Suppliers to the industry will gain value as well, and may offer much more affordable entry points. Think fertilizer suppliers, hydroponics lighting suppliers and marijuana greenhouse builders.
One company in this vein is Radient Technologies, (TSXV: RTI) trading at $0.99 a share as of August 29, 2018. Just to set this up a little, That Deloitte report linked at the top of this blog predicts that six out of ten Canadian marijuana consumers will opt for edibles as opposed to smoking. Radient makes marijuana extraction equipment that the company states offers higher and more pure yields at a lower price than any other method. The company holds a Dealers License from Health Canada for its research and development laboratory and expects to gain an ACMPR license by the end of this October. The company also has a partnership with Aurora to process marijuana for medical marijuana cannabinoids. Radient is expanding its reach to Europe.
It has also applied to the US Food and Drug Administration to consider its MAP technology, patent pending, as a method to reduce nicotine levels in tobacco. The company offers exposure to the medical marijuana market, edibles and the hemp market which largely consists of protein and consumer health supplements. The company is in the process of expanding its facilities.
Namaste Technologies, (TSXV: N) $1.84 as of August 29, 2018. Namaste Technologies has a chance at becoming the Amazon of Pot. The company is a medical marijuana licensed producer through subsidiary Cannmart. It is also much more than that.
Namaste started out as a medical marijuana e-commerce hub. The company believes that it is the largest online medical cannabis retailer in the world with operations in 20 countries. It has the majority market share in Europe and Australia, as well as operations in the UK, Canada and Germany. It is now entering the Brazilian and Mexican markets. Along with filling prescriptions Namaste also distributes vaporizers and accessories.
Its newest wrinkle is Namaste MD, which has been launched in Canada, an application that works on iphone and Android devices that allows medical marijuana consumers to book a video conference with a doctor, acquire a prescription and then fill the order with either a same day or two day delivery.
Through the application Namaste will also offer advice on the best strain to fit the prescription and offer a variety of growers’ products as well as imported medical marijuana. Given the success of Amazon and the public’s predilection for online ordering Namaste MD may very well prove a winner.
In Canada we tend to look only at our own markets when considering our marijuana stock options. When we look at Canadian powerhouses like Canopy Growth or Aurora we really don’t take into account their international operations or ambitions.
While Namaste offers international exposure to a market that is only growing larger so does up and comer Crop Infrastructure Corp. Trading on the CSE as CROP, shares had reached $0.29 by midday on August 29, 2018.
CROP was formed to address the problem that many licensed medical and recreational marijuana producers face in both emerging and American markets where recreational marijuana has been legalized. While marijuana has been legalized in numerous American states the federal government has not legalized consumption and federal regulations prohibit traditional sources of financing from lending to the marijuana sector.
One way to look at CROP is to see it as a REIT, a real estate investment trust because it owns, operates or finances income producing real estate.
As an investment vehicle CROP fills the financial need by providing the capital needed to set up marijuana production facilities from, buying the land to building the access roads foundations and greenhouses. The company makes its money through attractive leasing and management fees.
CROP Infrastructure Corp. loans capital to purchase real estate, which is leased to the licensed producers. The company receives a 60% preferential payback via lease and management fees on greenhouse infrastructure related equipment, until its deployed capital is returned in full. Once its investment is repaid in full, CROP’s 30% interest in the real estate & infrastructure will receive dividends indefinitely.
The company is a savvy operator, the cannabis being grown at its Washington State operation costs $200 a pound to grow or $0.44 a gram. The company has operations in California, Nevada and Washington State, Italy and Jamaica. Eventually it plans to operate in every jurisdiction that is legal including Canada, partnering with best in class producers. Crop also has a joint venture in dispensary applications in West Hollywood and San Bernardino. It has developed a portfolio of 15 cannabis brands and has the US and Italian distribution rights to a line of 55 topical cannabis products from the Yield Growth Corp. The company recently announced that Greg Douglas, the former CEO of Jamaica’s Cannabis Licensing Authority had joined Crop as a member of the Executive Advisory Board, with a special focus on Jamaican operations.
This blog should not be construed as investment advice. Investors should and must perform their own due diligence when considering stock investments.
- Published in Uncategorized
Auxico Closes First Tranche of Private Placement
Momentum Public Relations
Press Release: August 21 2018
Auxico Resources Canada Inc. (CSE: AUAG) is pleased to announce that it has completed the first tranche of a non-brokered private placement of 2,550,000 units (“Units”), issued at a price of $0.20 per Unit, for gross proceeds of $510,000. Each unit consists of one common share (“Common Share”) and one-half transferable common share purchase warrant (“Warrant”). Each full Warrant entitles the holder to acquire one additional Common Share of the Company at a price of $0.40 per Common Share for two years from the date of issuance.
The Company paid finder’s fees of $35,000 in connection with the private placement.
The net proceeds of the private placement will be used for geological work on the Company’s Zamora Property in Mexico and its mining interests in Colombia, and for general working capital. More specifically, Auxico will begin geological work in Colombia to evaluate coltan opportunities there, as per the Company’s news release of July 10, 2018.
The Company intends to close one or more additional tranches of this private placement on the same terms as presented above, for total gross proceeds (in all tranches) of up to $1,500,000.
Mark Billings, President of the Company stated, “We are very pleased with the support that we have received from investors in completing the first tranche of this private placement, and we publicly thank them for their confidence in Auxico. We also intend on closing additional tranches of this private placement, as the summer now draws to a close. Funds from the private placement will enable us to move ahead with our analysis of many interesting mining opportunities in Colombia.”
ON BEHALF OF THE BOARD OF DIRECTORS
« signed » | « signed » | |
Pierre Gauthier | Mark Billings | |
CEO, Auxico Resources Canada Inc. | President, Auxico Resources Canada Inc. | |
pg@auxicoresources.com | mb@auxicoresources.com | |
Cell: +1 514 299 0881 | Cell: +1 514 296 1641 |
About Auxico Resources Canada Inc.
Auxico Resources Canada Inc. (“Auxico”) is a Canadian company that was founded in 2014 and based in Montreal. Auxico is engaged in the acquisition, exploration and development of mineral properties in Colombia and Mexico.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
- Published in Uncategorized
SRG Graphite Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option
Momentum Public Relations
Press Release: June 15 2018
SRG Graphite Inc. (TSXV:SRG) (“SRG” or the “Company”) is pleased to announce that the syndicate of underwriters co-led by National Bank Financial Inc. and TD Securities Inc. and including Macquarie Capital Markets Canada Ltd., Beacon Securities Limited and Clarksons Platou Securities AS (collectively, the “Underwriters”) for its May 2018 public offering (the “Offering”) of units of the Company (“Units”) has fully exercised the over-allotment option (the “Over-Allotment Option”) granted under the Offering to purchase 800,100 additional Units at a price of $1.50 per Unit (the “Offering Price”) for additional gross proceeds to the Company of $1,200,150. This results in aggregate gross proceeds of the Offering, including the exercise of the Over-Allotment Option on the date hereof, of $9,201,150. In addition to the previously announced concurrent private placement with Coris Capital S.A., this brings the aggregate gross proceeds of the raise to $11,201,150.
Each Unit issued under the Over-Allotment Option is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one additional Common Share at an exercise price of $2.30 per Common Share at any time for a period of 12 months from the closing of the Offering as press released on May 18, 2018.
The Company intends to use the proceeds from the Offering and the Over-Allotment Option for advancement of the Company’s Lola graphite project, including, in the near term, to further regional exploration and infill resource drilling and to progress towards a feasibility study; for continued exploration of its Gogota cobalt-nickel-scandium project; and for general working capital purposes.
The Offering was made pursuant to a short form prospectus dated May 11, 2018 (the “Prospectus”), filed in each of the Provinces of Canada and available on SEDAR at www.sedar.com.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
ABOUT SRG
SRG is a Canadian-based company focused on developing the Lola graphite deposit and the Gogota cobalt-nickel-scandium deposit located in the Republic of Guinea, West Africa. SRG is committed to operating in a socially, environmentally and ethically responsible manner.
For additional information, please visit SRG’s website at www.srggraphite.com.
For more information contact: | |
Ugo Landry-Tolszczuk | Benoit La Salle, FCPA FCA |
Tel: +1 (514) 679-4196 | Tel: +1 (514) 951-4411 |
Email: ultolszczuk@srggraphite.com | Email: benoit.lasalle@srggraphite.com |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This press release contains “forward-looking information” within the meaning of Canadian securities legislation. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Generally, such forward-looking information can be identified by the use of forward-looking terminology such as “reduce”, “suggest”, “opportunity”, “demonstrate”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would” or “might” occur. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: (i) the Company’s use of proceeds of the Offering and the Over-Allotment Option may differ from those indicated; (ii) volatile stock price; (iii) the general global markets and economic conditions; (iv) the possibility of write-downs and impairments; (v) the risk associated with exploration, development and operations of mineral deposits; (vi) the risk associated with establishing title to mineral properties and assets; (vii) fluctuations in commodity prices and other risks and factors described or referred to in the sections entitled “Risk Factors” in the Annual Information Form of the Company and the Prospectus available at www.sedar.com, all of which should be reviewed in conjunction with the information found in this news release.
Forward-looking information is based on assumptions management believes to be reasonable at the time such statements are made, including but not limited to, continued exploration activities and no material adverse change in mineral prices. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Such forward-looking information has been provided for the purpose of assisting investors in understanding the Company’s business, operations and exploration plans and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is given as of the date of this press release, and the Company does not undertake to update such forward-looking information except in accordance with applicable securities laws.
- Published in SRG Graphite, Uncategorized